1. Home
  2. IKT vs TAVI Comparison

IKT vs TAVI Comparison

Compare IKT & TAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKT
  • TAVI
  • Stock Information
  • Founded
  • IKT 2008
  • TAVI 2024
  • Country
  • IKT United States
  • TAVI United States
  • Employees
  • IKT N/A
  • TAVI N/A
  • Industry
  • IKT Biotechnology: Pharmaceutical Preparations
  • TAVI
  • Sector
  • IKT Health Care
  • TAVI
  • Exchange
  • IKT Nasdaq
  • TAVI Nasdaq
  • Market Cap
  • IKT 140.5M
  • TAVI 163.7M
  • IPO Year
  • IKT 2020
  • TAVI 2024
  • Fundamental
  • Price
  • IKT $1.71
  • TAVI $10.27
  • Analyst Decision
  • IKT Buy
  • TAVI
  • Analyst Count
  • IKT 2
  • TAVI 0
  • Target Price
  • IKT $8.00
  • TAVI N/A
  • AVG Volume (30 Days)
  • IKT 117.1K
  • TAVI 2.6K
  • Earning Date
  • IKT 08-26-2025
  • TAVI 01-01-0001
  • Dividend Yield
  • IKT N/A
  • TAVI N/A
  • EPS Growth
  • IKT N/A
  • TAVI N/A
  • EPS
  • IKT N/A
  • TAVI 0.12
  • Revenue
  • IKT N/A
  • TAVI N/A
  • Revenue This Year
  • IKT N/A
  • TAVI N/A
  • Revenue Next Year
  • IKT N/A
  • TAVI N/A
  • P/E Ratio
  • IKT N/A
  • TAVI $83.19
  • Revenue Growth
  • IKT N/A
  • TAVI N/A
  • 52 Week Low
  • IKT $1.12
  • TAVI $9.89
  • 52 Week High
  • IKT $4.20
  • TAVI $10.72
  • Technical
  • Relative Strength Index (RSI)
  • IKT 49.23
  • TAVI N/A
  • Support Level
  • IKT $1.42
  • TAVI N/A
  • Resistance Level
  • IKT $1.83
  • TAVI N/A
  • Average True Range (ATR)
  • IKT 0.15
  • TAVI 0.00
  • MACD
  • IKT 0.00
  • TAVI 0.00
  • Stochastic Oscillator
  • IKT 62.11
  • TAVI 0.00

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

About TAVI Tavia Acquisition Corp. Ordinary Shares

Tavia Acquisition Corp is a blank check company.

Share on Social Networks: